Kappa free light chain (KFLC) index in clinically isolated syndrome.... | Download Scientific Diagram
![Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial](https://www.mdpi.com/cancers/cancers-13-04856/article_deploy/html/images/cancers-13-04856-g001.png)
Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
![Serum-free light-chain assay: clinical utility and limitations - Malini V Bhole, Ross Sadler, Karthik Ramasamy, 2014 Serum-free light-chain assay: clinical utility and limitations - Malini V Bhole, Ross Sadler, Karthik Ramasamy, 2014](https://journals.sagepub.com/cms/10.1177/0004563213518758/asset/images/large/10.1177_0004563213518758-fig1.jpeg)
Serum-free light-chain assay: clinical utility and limitations - Malini V Bhole, Ross Sadler, Karthik Ramasamy, 2014
Manni Mohyuddin on Twitter: "Thus in normal situations, kappa/lambda ratio is actually usually slightly less than 1, since lambda sticks around in blood more than kappa." / Twitter
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Tr
![Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial](https://www.mdpi.com/cancers/cancers-13-04856/article_deploy/html/images/cancers-13-04856-g003-550.jpg)
Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum | Communications Biology Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum | Communications Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs42003-020-01515-x/MediaObjects/42003_2020_1515_Fig1_HTML.png)
Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum | Communications Biology
Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease | PLOS ONE
![Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum | Communications Biology Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum | Communications Biology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs42003-020-01515-x/MediaObjects/42003_2020_1515_Fig2_HTML.png)